FusionGDB Logo

Home

Download

Statistics

Examples

Help

Contact

Center for Computational Systems Medicine
leaf

FusionGeneSummary

leaf

FusionProtFeature

leaf

FusionGeneSequence

leaf

FusionGenePPI

leaf

RelatedDrugs

leaf

RelatedDiseases

Fusion gene ID: 28713

FusionGeneSummary for PRKCA_EFNA3

check button Fusion gene summary
Fusion gene informationFusion gene name: PRKCA_EFNA3
Fusion gene ID: 28713
HgeneTgene
Gene symbol

PRKCA

EFNA3

Gene ID

5578

1944

Gene nameprotein kinase C alphaephrin A3
SynonymsAAG6|PKC-alpha|PKCA|PRKACAEFL2|EPLG3|Ehk1-L|LERK3
Cytomap

17q24.2

1q21.3

Type of geneprotein-codingprotein-coding
Descriptionprotein kinase C alpha typePKC-Aaging-associated gene 6ephrin-A3EFL-2EHK1 ligandLERK-3eph-related receptor tyrosine kinase ligand 3ligand of eph-related kinase 3
Modification date2018052320180523
UniProtAcc

P17252

P52797

Ensembl transtripts involved in fusion geneENST00000413366, ENST00000583361, 
ENST00000556931, ENST00000505139, 
ENST00000368408, ENST00000418360, 
ENST00000498667, 
Fusion gene scores* DoF score27 X 12 X 10=32402 X 1 X 2=4
# samples 292
** MAII scorelog2(29/3240*10)=-3.48186900775705
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
log2(2/4*10)=2.32192809488736
Context

PubMed: PRKCA [Title/Abstract] AND EFNA3 [Title/Abstract] AND fusion [Title/Abstract]

Functional or gene categories assigned by FusionGDB annotation
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

check button Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez
PartnerGeneGO IDGO termPubMed ID
HgenePRKCA

GO:0006468

protein phosphorylation

10770950

HgenePRKCA

GO:0035408

histone H3-T6 phosphorylation

20228790

HgenePRKCA

GO:0043536

positive regulation of blood vessel endothelial cell migration

20011604

HgenePRKCA

GO:0090330

regulation of platelet aggregation

12724315

TgeneEFNA3

GO:0016525

negative regulation of angiogenesis

18417479


check button Fusion gene information from three resources
(ChiTars (NAR, 2018), tumorfusions (NAR, 2018), Gao et al. (Cell, 2018))
* All genome coordinats were lifted-over on hg19.
* Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser.
Data typeSourceCancer typeSampleHgeneHchrHbpHstrandTgeneTchrTbpTstrand
TCGALDLIHCTCGA-LG-A9QC-01APRKCAchr17

64302245

+EFNA3chr1

155057567

+
* LD: Li Ding group's fusion gene list
  RV: Roel Verhaak group's fusion gene list
  ChiTaRs fusion database

check button Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure.
* Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser.
ORFHenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrand
Frame-shiftENST00000413366ENST00000556931PRKCAchr17

64302245

+EFNA3chr1

155057567

+
Frame-shiftENST00000413366ENST00000505139PRKCAchr17

64302245

+EFNA3chr1

155057567

+
Frame-shiftENST00000413366ENST00000368408PRKCAchr17

64302245

+EFNA3chr1

155057567

+
Frame-shiftENST00000413366ENST00000418360PRKCAchr17

64302245

+EFNA3chr1

155057567

+
5CDS-intronENST00000413366ENST00000498667PRKCAchr17

64302245

+EFNA3chr1

155057567

+
3UTR-3CDSENST00000583361ENST00000556931PRKCAchr17

64302245

+EFNA3chr1

155057567

+
3UTR-3CDSENST00000583361ENST00000505139PRKCAchr17

64302245

+EFNA3chr1

155057567

+
3UTR-3CDSENST00000583361ENST00000368408PRKCAchr17

64302245

+EFNA3chr1

155057567

+
3UTR-3CDSENST00000583361ENST00000418360PRKCAchr17

64302245

+EFNA3chr1

155057567

+
3UTR-intronENST00000583361ENST00000498667PRKCAchr17

64302245

+EFNA3chr1

155057567

+

Top

FusionProtFeatures for PRKCA_EFNA3


check buttonMain function of each fusion partner protein. (from UniProt)
HgeneTgene
PRKCA

P17252

EFNA3

P52797

Calcium-activated, phospholipid- and diacylglycerol(DAG)-dependent serine/threonine-protein kinase that is involvedin positive and negative regulation of cell proliferation,apoptosis, differentiation, migration and adhesion, tumorigenesis,cardiac hypertrophy, angiogenesis, platelet function andinflammation, by directly phosphorylating targets such as RAF1,BCL2, CSPG4, TNNT2/CTNT, or activating signaling cascade involvingMAPK1/3 (ERK1/2) and RAP1GAP. Involved in cell proliferation andcell growth arrest by positive and negative regulation of the cellcycle. Can promote cell growth by phosphorylating and activatingRAF1, which mediates the activation of the MAPK/ERK signalingcascade, and/or by up-regulating CDKN1A, which facilitates activecyclin-dependent kinase (CDK) complex formation in glioma cells.In intestinal cells stimulated by the phorbol ester PMA, cantrigger a cell cycle arrest program which is associated with theaccumulation of the hyper-phosphorylated growth-suppressive formof RB1 and induction of the CDK inhibitors CDKN1A and CDKN1B.Exhibits anti-apoptotic function in glioma cells and protects themfrom apoptosis by suppressing the p53/TP53-mediated activation ofIGFBP3, and in leukemia cells mediates anti-apoptotic action byphosphorylating BCL2. During macrophage differentiation induced bymacrophage colony-stimulating factor (CSF1), is translocated tothe nucleus and is associated with macrophage development. Afterwounding, translocates from focal contacts to lamellipodia andparticipates in the modulation of desmosomal adhesion. Plays arole in cell motility by phosphorylating CSPG4, which inducesassociation of CSPG4 with extensive lamellipodia at the cellperiphery and polarization of the cell accompanied by increases incell motility. During chemokine-induced CD4(+) T cell migration,phosphorylates CDC42-guanine exchange factor DOCK8 resulting inits dissociation from LRCH1 and the activation of GTPase CDC42(PubMed:28028151). Is highly expressed in a number of cancer cellswhere it can act as a tumor promoter and is implicated inmalignant phenotypes of several tumors such as gliomas and breastcancers. Negatively regulates myocardial contractility andpositively regulates angiogenesis, platelet aggregation andthrombus formation in arteries. Mediates hypertrophic growth ofneonatal cardiomyocytes, in part through a MAPK1/3 (ERK1/2)-dependent signaling pathway, and upon PMA treatment, is requiredto induce cardiomyocyte hypertrophy up to heart failure and death,by increasing protein synthesis, protein-DNA ratio and cellsurface area. Regulates cardiomyocyte function by phosphorylatingcardiac troponin T (TNNT2/CTNT), which induces significantreduction in actomyosin ATPase activity, myofilament calciumsensitivity and myocardial contractility. In angiogenesis, isrequired for full endothelial cell migration, adhesion tovitronectin (VTN), and vascular endothelial growth factor A(VEGFA)-dependent regulation of kinase activation and vasculartube formation. Involved in the stabilization of VEGFA mRNA atpost-transcriptional level and mediates VEGFA-induced cellproliferation. In the regulation of calcium-induced plateletaggregation, mediates signals from the CD36/GP4 receptor forgranule release, and activates the integrin heterodimer ITGA2B-ITGB3 through the RAP1GAP pathway for adhesion. During response tolipopolysaccharides (LPS), may regulate selective LPS-inducedmacrophage functions involved in host defense and inflammation.But in some inflammatory responses, may negatively regulate NF-kappa-B-induced genes, through IL1A-dependent induction of NF-kappa-B inhibitor alpha (NFKBIA/IKBA). Upon stimulation with 12-O-tetradecanoylphorbol-13-acetate (TPA), phosphorylates EIF4G1,which modulates EIF4G1 binding to MKNK1 and may be involved in theregulation of EIF4E phosphorylation. Phosphorylates KIT, leadingto inhibition of KIT activity. Phosphorylates ATF2 which promotescooperation between ATF2 and JUN, activating transcription.{ECO:0000269|PubMed:10848585, ECO:0000269|PubMed:11909826,ECO:0000269|PubMed:12724315, ECO:0000269|PubMed:12832403,ECO:0000269|PubMed:15016832, ECO:0000269|PubMed:15504744,ECO:0000269|PubMed:15526160, ECO:0000269|PubMed:18056764,ECO:0000269|PubMed:19176525, ECO:0000269|PubMed:21576361,ECO:0000269|PubMed:23990668, ECO:0000269|PubMed:28028151,ECO:0000269|PubMed:9738012, ECO:0000269|PubMed:9830023,ECO:0000269|PubMed:9873035, ECO:0000269|PubMed:9927633}. Cell surface GPI-bound ligand for Eph receptors, afamily of receptor tyrosine kinases which are crucial formigration, repulsion and adhesion during neuronal, vascular andepithelial development. Binds promiscuously Eph receptors residingon adjacent cells, leading to contact-dependent bidirectionalsignaling into neighboring cells. The signaling pathway downstreamof the receptor is referred to as forward signaling while thesignaling pathway downstream of the ephrin ligand is referred toas reverse signaling (By similarity). {ECO:0000250}.

check buttonRetention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at

download page

.

* Minus value of BPloci means that the break pointn is located before the CDS.
- In-frame and retained protein feature among the 13 regional features.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note

- In-frame and not-retained protein feature among the 13 regional features.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note


Top

FusionGeneSequence for PRKCA_EFNA3


check button For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences.
(nt: nucleotides, aa: amino acids)

* Fusion amino acid sequences.

* Fusion transcript sequences (only coding sequence (CDS) region).

* Fusion transcript sequences (Full-length transcript).

Top

FusionGenePPI for PRKCA_EFNA3


check button Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in

ChiPPI page

.

check button Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160)
HgeneHgene's interactorsTgeneTgene's interactors
PRKCAATP1A1, HABP4, HAND1, HAND2, FSCN1, EGFR, SLC1A1, PLD1, KLF5, GABRB3, MGMT, PLD2, PICK1, GRM7, AKAP12, GJA1, YWHAG, C1QBP, AVPR1A, AVPR1B, GSK3B, RGS2, OGG1, YWHAZ, TIAM1, GNB2L1, ITGB1, AFAP1, EZR, DLG4, LMNB1, LMNA, CD53, CD9, TRIM41, HMGA1, HMGA2, TNP1, TNP2, HIST1H3A, CHUK, IKBKB, NFE2L2, PRKCA, MTOR, TRPV6, AKAP5, DDX58, HIST1H1A, HIST1H1B, HIST1H1C, HIST1H1D, HIST1H1E, HIST1H1T, EIF4EBP1, MBP, HDAC6, CTNNB1, NR1H2, ELAVL1, HIST3H3, ANXA6, LNX1, LNX2, GLI3, IBTK, SCRIB, CBL, TOP2A, RICTOR, MAPKAP1, SELL, PFKFB1, NCF1, ACIN1, DSP, RALBP1, PPP1R14A, PLCG2, VTN, SDC2, ITGB2, HSP90AA1, GSK3A, GRIN1, GRIN2B, CASR, RRAD, NFKBIA, HMGN1, HMGN2, NPM1, NUMB, FBXO25, CDKN2A, PSMB4, SACM1L, PTGIR, TBXA2R, CYP3A4, RBCK1, RNF31, MOV10, NXF1, EP300, PPARG, CCDC8, EIF2S1, SLC25A41, SLC25A11, TAS2R7, TMEM185A, JSRP1, CCNL2, VPS4B, UQCRB, WWC2, WWC3, WWC1, MAPK7, NTRK1, NOXA1, GRM5, AKAP13, STXBP1, SPAG1, BTG2, CACYBP, SLC9A3R1, SLC9A3R2, KIF2A, KIF11, FAS, NF2, PLA2G4A, SMURF1, PRKCB, PRKCG, PRKCH, PIP5K1A, SHCBP1, GCLM, STARD7, CYP2S1, FGD4, DUSP11, FBXO21, HR, PPM1A, ATM, TESEFNA3PRSS23, EPHA7, EPHA3, MEOX2, KRTAP10-3, NOTCH2NL


check button - Retained PPIs in in-frame fusion.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenStill interaction with


check button - Lost PPIs in in-frame fusion.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenInteraction lost with


check button - Retained PPIs, but lost function due to frame-shift fusion.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenInteraction lost with


Top

RelatedDrugs for PRKCA_EFNA3


check button Drugs targeting genes involved in this fusion gene.
(DrugBank Version 5.1.0 2018-04-02)
PartnerGeneUniProtAccDrugBank IDDrug nameDrug activityDrug typeDrug status
HgenePRKCAP17252DB00675TamoxifenProtein kinase C alpha typesmall moleculeapproved
HgenePRKCAP17252DB05013Ingenol MebutateProtein kinase C alpha typesmall moleculeapproved

Top

RelatedDiseases for PRKCA_EFNA3


check button Diseases associated with fusion partners.
(DisGeNet 4.0)
PartnerGeneDisease IDDisease name# pubmedsSource
HgenePRKCAC0036341Schizophrenia2PSYGENET
HgenePRKCAC0011853Diabetes Mellitus, Experimental1CTD_human
HgenePRKCAC0018800Cardiomegaly1CTD_human
HgenePRKCAC0021841Intestinal Neoplasms1CTD_human
HgenePRKCAC0032617Polyuria1CTD_human
HgenePRKCAC0033975Psychotic Disorders1PSYGENET
HgenePRKCAC0036337Schizoaffective Disorder1PSYGENET
HgenePRKCAC0162283Nephrogenic Diabetes Insipidus1CTD_human
HgenePRKCAC0349204Nonorganic psychosis1PSYGENET